gp	Other
psychosomatic specialist consultation in gp 's office	Other
high level of acceptance among patient	design
high level of acceptance among patient	stimulation
provider	components
real world	Other
treatment of choice for generalised anxiety disorder	first-onset
treatment of choice for generalised anxiety disorder	hippocampal
treatment of choice for generalised anxiety disorder	stimulation
treatment of choice for generalised anxiety disorder	psychotropics
treatment of choice for generalised anxiety disorder	reported
treatment of choice for generalised anxiety disorder	death
treatment of choice for generalised anxiety disorder	mood
treatment of choice for generalised anxiety disorder	lithium
especially recovery	Other
older adult	lithium
mortality	Other
non-specific	ECT
Parkinson 's disease	lithium
related	first-onset
related	hippocampal
literature	lithium
cognitive behavior like learning	complement
cognitive behavior like learning	hippocampal
cognitive behavior like learning	stimulation
cognitive behavior like learning	ECT
cognitive behavior like learning	reported
cognitive behavior like learning	mood
could compromise by effect of apomorphine	apomorphine
latest information about its effect on hippocampus	framework
latest information about its effect on hippocampus	components
recent-onset schizophrenia	design
recent-onset schizophrenia	EDT
recent-onset schizophrenia	ECT
recent-onset schizophrenia	lithium
mechanism involve	CYB5R3
mechanism involve	complement
mechanism involve	stimulation
numerous way	Other
they difficult experience	Other
physical health across mental disorder	biomarker
physical health across mental disorder	hippocampal
physical health across mental disorder	reported
physical health across mental disorder	death
physical health across mental disorder	mood
physical health across mental disorder	lithium
people with mental illness	framework
people with mental illness	fasting
people with mental illness	psychotropics
lower incidence of relapse	health-based
lower incidence of relapse	design
primary health care	electronic
primary health care	apomorphine
primary health care	death
primary health care	mood
primary health care	lithium
somatic complaint	Other
deal with patient	design
should evaluate	Other
patient with systemic lupus erythematosus receive	design
characterise	Other
severe developmental complication	biomarker
severe developmental complication	complement
treatment	first-onset
treatment	hippocampal
treatment	stimulation
treatment	psychotropics
treatment	reported
treatment	death
treatment	mood
basis of dominant family system theory	Other
neonatal outcome include gestational age	hippocampal
neonatal outcome include gestational age	stimulation
neonatal outcome include gestational age	psychotropics
neonatal outcome include gestational age	reported
neonatal outcome include gestational age	death
anxiety in adult with autism spectrum disorder	hippocampal
anxiety in adult with autism spectrum disorder	psychotropics
anxiety in adult with autism spectrum disorder	reported
anxiety in adult with autism spectrum disorder	death
anxiety in adult with autism spectrum disorder	lithium
adult	lithium
effective	hippocampal
effective	Demoralization
effective	EDT
effective	stimulation
effective	reported
effective	mood
effect of ECT on functional connectivity of brain hub in depression patient	CYB5R3
effect of ECT on functional connectivity of brain hub in depression patient	complement
effect of ECT on functional connectivity of brain hub in depression patient	apomorphine
effect of ECT on functional connectivity of brain hub in depression patient	components
effect of ECT on functional connectivity of brain hub in depression patient	design
effect of ECT on functional connectivity of brain hub in depression patient	ECT
in current study assess at three time point	electronic
in current study assess at three time point	apomorphine
in current study assess at three time point	design
clinical symptom	complement
clinical symptom	hippocampal
clinical symptom	stimulation
clinical symptom	psychotropics
clinical symptom	reported
clinical symptom	death
clinical symptom	mood
brain hub	CYB5R3
brain hub	components
ECT	CYB5R3
ECT	apomorphine
ECT	ECT
1 month after completion of ECT	CYB5R3
1 month after completion of ECT	apomorphine
1 month after completion of ECT	ECT
1 month after completion of ECT	lithium
functional connectivity of left angular gyrus	Other
most frequently diagnose mental health problem among american college student	first-onset
most frequently diagnose mental health problem among american college student	EDT
most frequently diagnose mental health problem among american college student	death
most frequently diagnose mental health problem among american college student	mood
most frequently diagnose mental health problem among american college student	lithium
mental/cognitive disability arise	complement
mental/cognitive disability arise	hippocampal
mental/cognitive disability arise	ECT
mental/cognitive disability arise	reported
type of EDT student	electronic
type of EDT student	apomorphine
type of EDT student	components
type of EDT student	EDT
research indicate	biomarker
research indicate	CYB5R3
they anxiety	psychotropics
they anxiety	reported
they anxiety	lithium
continue	Other
peer run technology group teach by interested student	Other
would topic for group discussion	Demoralization
part of they life	Other
they	Other
mainstay treatment in bipolar disorder for its effectiveness in acute phase of illness in prevention of recurrence	CYB5R3
mainstay treatment in bipolar disorder for its effectiveness in acute phase of illness in prevention of recurrence	electronic
mainstay treatment in bipolar disorder for its effectiveness in acute phase of illness in prevention of recurrence	first-onset
mainstay treatment in bipolar disorder for its effectiveness in acute phase of illness in prevention of recurrence	hippocampal
mainstay treatment in bipolar disorder for its effectiveness in acute phase of illness in prevention of recurrence	Demoralization
mainstay treatment in bipolar disorder for its effectiveness in acute phase of illness in prevention of recurrence	EDT
mainstay treatment in bipolar disorder for its effectiveness in acute phase of illness in prevention of recurrence	stimulation
mainstay treatment in bipolar disorder for its effectiveness in acute phase of illness in prevention of recurrence	psychotropics
mainstay treatment in bipolar disorder for its effectiveness in acute phase of illness in prevention of recurrence	reported
mainstay treatment in bipolar disorder for its effectiveness in acute phase of illness in prevention of recurrence	death
mainstay treatment in bipolar disorder for its effectiveness in acute phase of illness in prevention of recurrence	mood
mechanism of action	CYB5R3
mechanism of action	complement
mechanism of action	hippocampal
mechanism of action	stimulation
mechanism of action	death
mechanism of action	mood
integrate analytical approach	Other
effect of treatment with lithium chloride 1 mm on transcriptome of lymphoblast	biomarker
effect of treatment with lithium chloride 1 mm on transcriptome of lymphoblast	first-onset
effect of treatment with lithium chloride 1 mm on transcriptome of lymphoblast	hippocampal
effect of treatment with lithium chloride 1 mm on transcriptome of lymphoblast	stimulation
effect of treatment with lithium chloride 1 mm on transcriptome of lymphoblast	psychotropics
effect of treatment with lithium chloride 1 mm on transcriptome of lymphoblast	reported
effect of treatment with lithium chloride 1 mm on transcriptome of lymphoblast	death
effect of treatment with lithium chloride 1 mm on transcriptome of lymphoblast	mood
effect of treatment with lithium chloride 1 mm on transcriptome of lymphoblast	lithium
gene-based analysis on genome-wide genotyping datum from extended sample of 205 bd patient characterize for lithium response	biomarker
gene-based analysis on genome-wide genotyping datum from extended sample of 205 bd patient characterize for lithium response	addiction
gene-based analysis on genome-wide genotyping datum from extended sample of 205 bd patient characterize for lithium response	CYB5R3
gene-based analysis on genome-wide genotyping datum from extended sample of 205 bd patient characterize for lithium response	fear
gene-based analysis on genome-wide genotyping datum from extended sample of 205 bd patient characterize for lithium response	framework
gene-based analysis on genome-wide genotyping datum from extended sample of 205 bd patient characterize for lithium response	fasting
gene-based analysis on genome-wide genotyping datum from extended sample of 205 bd patient characterize for lithium response	design
gene-based analysis on genome-wide genotyping datum from extended sample of 205 bd patient characterize for lithium response	ECT
gene-based analysis on genome-wide genotyping datum from extended sample of 205 bd patient characterize for lithium response	lithium
LR	Other
quantitative real-time polymerase chain reaction	hippocampal
quantitative real-time polymerase chain reaction	design
quantitative real-time polymerase chain reaction	death
quantitative real-time polymerase chain reaction	mood
convergent analysis of genome-wide expression	ECT
convergent analysis of genome-wide expression	lithium
involvement of zinc finger protein in lithium response	biomarker
involvement of zinc finger protein in lithium response	lithium
child 's mental health	CYB5R3
child 's mental health	death
child 's mental health	mood
child 's mental health	lithium
still its infancy	components
serious mental illness such schizophrenia	design
serious mental illness such schizophrenia	psychotropics
serious mental illness such schizophrenia	ECT
life	Other
effectiveness of group lifestyle intervention enhance with mobile health technology	CYB5R3
effectiveness of group lifestyle intervention enhance with mobile health technology	electronic
effectiveness of group lifestyle intervention enhance with mobile health technology	hippocampal
effectiveness of group lifestyle intervention enhance with mobile health technology	Demoralization
effectiveness of group lifestyle intervention enhance with mobile health technology	EDT
effectiveness of group lifestyle intervention enhance with mobile health technology	stimulation
effectiveness of group lifestyle intervention enhance with mobile health technology	reported
effectiveness of group lifestyle intervention enhance with mobile health technology	death
effectiveness of group lifestyle intervention enhance with mobile health technology	mood
effectiveness of group lifestyle intervention enhance with mobile health technology	lithium
have associate with development of various mental disorder	biomarker
have associate with development of various mental disorder	complement
have associate with development of various mental disorder	hippocampal
have associate with development of various mental disorder	health-based
have associate with development of various mental disorder	reported
have associate with development of various mental disorder	death
course of psychotherapy	Other
comprehensive review of psychotherapeutic intervention effect on hpa axis in adult sample with mental disorder	addiction
comprehensive review of psychotherapeutic intervention effect on hpa axis in adult sample with mental disorder	fear
comprehensive review of psychotherapeutic intervention effect on hpa axis in adult sample with mental disorder	framework
comprehensive review of psychotherapeutic intervention effect on hpa axis in adult sample with mental disorder	hippocampal
comprehensive review of psychotherapeutic intervention effect on hpa axis in adult sample with mental disorder	fasting
comprehensive review of psychotherapeutic intervention effect on hpa axis in adult sample with mental disorder	design
comprehensive review of psychotherapeutic intervention effect on hpa axis in adult sample with mental disorder	ECT
comprehensive review of psychotherapeutic intervention effect on hpa axis in adult sample with mental disorder	reported
comprehensive review of psychotherapeutic intervention effect on hpa axis in adult sample with mental disorder	death
comprehensive review of psychotherapeutic intervention effect on hpa axis in adult sample with mental disorder	lithium
four database for psychotherapeutic intervention study with mentally ill patient sample	addiction
four database for psychotherapeutic intervention study with mentally ill patient sample	electronic
four database for psychotherapeutic intervention study with mentally ill patient sample	fear
four database for psychotherapeutic intervention study with mentally ill patient sample	framework
four database for psychotherapeutic intervention study with mentally ill patient sample	fasting
four database for psychotherapeutic intervention study with mentally ill patient sample	design
four database for psychotherapeutic intervention study with mentally ill patient sample	ECT
examine	electronic
include	Other
study	electronic
unfeasible	Other
comprehensively review	Other
strong	Other
comparability of psychotherapeutic treatment effect	first-onset
comparability of psychotherapeutic treatment effect	hippocampal
comparability of psychotherapeutic treatment effect	stimulation
comparability of psychotherapeutic treatment effect	psychotropics
comparability of psychotherapeutic treatment effect	ECT
comparability of psychotherapeutic treatment effect	reported
comparability of psychotherapeutic treatment effect	death
comparability of psychotherapeutic treatment effect	mood
adult with high-functioning autism	stimulation
adult with high-functioning autism	lithium
disorder	hippocampal
disorder	reported
disorder	death
information in different format aim	components
intervention	Other
user ' naturalistic environment	first-onset
user ' naturalistic environment	hippocampal
user ' naturalistic environment	EDT
user ' naturalistic environment	psychotropics
user ' naturalistic environment	reported
user ' naturalistic environment	death
user ' naturalistic environment	mood
outpatient court-ordered treatment for people in part to treatment non-adherence	first-onset
outpatient court-ordered treatment for people in part to treatment non-adherence	framework
outpatient court-ordered treatment for people in part to treatment non-adherence	hippocampal
outpatient court-ordered treatment for people in part to treatment non-adherence	fasting
outpatient court-ordered treatment for people in part to treatment non-adherence	design
outpatient court-ordered treatment for people in part to treatment non-adherence	stimulation
outpatient court-ordered treatment for people in part to treatment non-adherence	psychotropics
outpatient court-ordered treatment for people in part to treatment non-adherence	reported
outpatient court-ordered treatment for people in part to treatment non-adherence	death
outpatient court-ordered treatment for people in part to treatment non-adherence	mood
update on recent research	EDT
motor symptom	Other
we knowledge of mechanism involve in development of behavioral addiction	biomarker
we knowledge of mechanism involve in development of behavioral addiction	addiction
we knowledge of mechanism involve in development of behavioral addiction	CYB5R3
we knowledge of mechanism involve in development of behavioral addiction	electronic
we knowledge of mechanism involve in development of behavioral addiction	complement
we knowledge of mechanism involve in development of behavioral addiction	fear
we knowledge of mechanism involve in development of behavioral addiction	framework
we knowledge of mechanism involve in development of behavioral addiction	fasting
we knowledge of mechanism involve in development of behavioral addiction	design
we knowledge of mechanism involve in development of behavioral addiction	stimulation
we knowledge of mechanism involve in development of behavioral addiction	mood
association with development of addictive behavior in pd include role of dopaminergic medication	biomarker
association with development of addictive behavior in pd include role of dopaminergic medication	complement
association with development of addictive behavior in pd include role of dopaminergic medication	Demoralization
association with development of addictive behavior in pd include role of dopaminergic medication	stimulation
association with development of addictive behavior in pd include role of dopaminergic medication	mood
neurobiology of addictive behavior	stimulation
neurobiology of addictive behavior	mood
milder form of hiv-1-associated neurocognitive disorder	first-onset
milder form of hiv-1-associated neurocognitive disorder	complement
milder form of hiv-1-associated neurocognitive disorder	hippocampal
milder form of hiv-1-associated neurocognitive disorder	ECT
milder form of hiv-1-associated neurocognitive disorder	reported
milder form of hiv-1-associated neurocognitive disorder	death
past several decade	CYB5R3
past several decade	ECT
risk factor for first-onset si among high-risk group	biomarker
risk factor for first-onset si among high-risk group	addiction
risk factor for first-onset si among high-risk group	first-onset
risk factor for first-onset si among high-risk group	fear
risk factor for first-onset si among high-risk group	framework
risk factor for first-onset si among high-risk group	fasting
risk factor for first-onset si among high-risk group	design
risk factor for first-onset si among high-risk group	stimulation
risk factor for first-onset si among high-risk group	lithium
National Treatment Improvement evaluation study	electronic
lifetime history of suicide attempt	Demoralization
lifetime history of suicide attempt	design
lifetime history of suicide attempt	psychotropics
lifetime history of suicide attempt	reported
lifetime history of suicide attempt	lithium
evaluate as prospective predictor of first-onset SI in linear regression model	biomarker
evaluate as prospective predictor of first-onset SI in linear regression model	addiction
evaluate as prospective predictor of first-onset SI in linear regression model	CYB5R3
evaluate as prospective predictor of first-onset SI in linear regression model	electronic
evaluate as prospective predictor of first-onset SI in linear regression model	first-onset
evaluate as prospective predictor of first-onset SI in linear regression model	fear
evaluate as prospective predictor of first-onset SI in linear regression model	apomorphine
evaluate as prospective predictor of first-onset SI in linear regression model	framework
evaluate as prospective predictor of first-onset SI in linear regression model	fasting
evaluate as prospective predictor of first-onset SI in linear regression model	design
evaluate as prospective predictor of first-onset SI in linear regression model	lithium
current mental health	apomorphine
current mental health	death
current mental health	mood
current mental health	lithium
importance of treatment accessibility	first-onset
importance of treatment accessibility	hippocampal
importance of treatment accessibility	stimulation
importance of treatment accessibility	psychotropics
importance of treatment accessibility	reported
importance of treatment accessibility	death
importance of treatment accessibility	mood
substance abuse program	biomarker
substance abuse program	first-onset
substance abuse program	hippocampal
substance abuse program	EDT
substance abuse program	psychotropics
substance abuse program	reported
substance abuse program	death
substance abuse program	mood
non-athlete	lithium
train at higher intensity for longer period of time	design
train at higher intensity for longer period of time	stimulation
train at higher intensity for longer period of time	ECT
unhealthy physical-activity pattern	biomarker
unhealthy physical-activity pattern	hippocampal
unhealthy physical-activity pattern	death
unhealthy physical-activity pattern	mood
unhealthy physical-activity pattern	lithium
non-athlete sample	addiction
non-athlete sample	fear
non-athlete sample	framework
non-athlete sample	fasting
non-athlete sample	design
non-athlete sample	lithium
clinically useful self-report measure of unhealthy training behavior	first-onset
clinically useful self-report measure of unhealthy training behavior	complement
clinically useful self-report measure of unhealthy training behavior	hippocampal
clinically useful self-report measure of unhealthy training behavior	EDT
clinically useful self-report measure of unhealthy training behavior	stimulation
clinically useful self-report measure of unhealthy training behavior	psychotropics
clinically useful self-report measure of unhealthy training behavior	reported
clinically useful self-report measure of unhealthy training behavior	death
clinically useful self-report measure of unhealthy training behavior	mood
clinically useful self-report measure of unhealthy training behavior	lithium
add to revise dsm-5 Feeding in 2013	Other
clinical setting	complement
clinical setting	hippocampal
clinical setting	stimulation
clinical setting	psychotropics
clinical setting	reported
clinical setting	death
clinical setting	mood
clinical setting	lithium
preliminary report on feasibility in relation to ARFID	components
more prevalent	Other
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	addiction
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	CYB5R3
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	first-onset
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	complement
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	fear
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	framework
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	hippocampal
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	health-based
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	fasting
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	design
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	EDT
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	stimulation
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	psychotropics
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	reported
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	death
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	mood
clinically relevant update of recent select key publication regard use of atypical antipsychotic in population	lithium
patient 's risk of social drift	design
short-term economic cost of fep program include direct cost	Other
neuroimaging biomarker for psychiatric disorder	biomarker
neuroimaging biomarker for psychiatric disorder	hippocampal
neuroimaging biomarker for psychiatric disorder	stimulation
neuroimaging biomarker for psychiatric disorder	reported
neuroimaging biomarker for psychiatric disorder	death
primary psychiatric disorder	electronic
primary psychiatric disorder	apomorphine
primary psychiatric disorder	hippocampal
primary psychiatric disorder	stimulation
primary psychiatric disorder	reported
primary psychiatric disorder	death
key pathological feature associate with hiv-associated neurocognitive disorder	first-onset
key pathological feature associate with hiv-associated neurocognitive disorder	complement
key pathological feature associate with hiv-associated neurocognitive disorder	hippocampal
key pathological feature associate with hiv-associated neurocognitive disorder	EDT
key pathological feature associate with hiv-associated neurocognitive disorder	ECT
key pathological feature associate with hiv-associated neurocognitive disorder	reported
key pathological feature associate with hiv-associated neurocognitive disorder	death
inhibit by cart	Other
loss	Other
same level of tat-induced synapse loss as wild-type mouse	electronic
same level of tat-induced synapse loss as wild-type mouse	first-onset
same level of tat-induced synapse loss as wild-type mouse	apomorphine
same level of tat-induced synapse loss as wild-type mouse	components
same level of tat-induced synapse loss as wild-type mouse	hippocampal
same level of tat-induced synapse loss as wild-type mouse	EDT
same level of tat-induced synapse loss as wild-type mouse	psychotropics
same level of tat-induced synapse loss as wild-type mouse	reported
same level of tat-induced synapse loss as wild-type mouse	death
same level of tat-induced synapse loss as wild-type mouse	mood
emerge experimental therapy for treatment-resistant depression	first-onset
emerge experimental therapy for treatment-resistant depression	complement
emerge experimental therapy for treatment-resistant depression	hippocampal
emerge experimental therapy for treatment-resistant depression	stimulation
emerge experimental therapy for treatment-resistant depression	psychotropics
emerge experimental therapy for treatment-resistant depression	reported
emerge experimental therapy for treatment-resistant depression	death
emerge experimental therapy for treatment-resistant depression	mood
specific axonal pathway	ECT
most detailed patient-specific foundation for DBS modeling currently available	CYB5R3
most detailed patient-specific foundation for DBS modeling currently available	electronic
most detailed patient-specific foundation for DBS modeling currently available	apomorphine
most detailed patient-specific foundation for DBS modeling currently available	design
most detailed patient-specific foundation for DBS modeling currently available	ECT
most detailed patient-specific foundation for DBS modeling currently available	lithium
scc region	Other
linear model predict	CYB5R3
linear model predict	electronic
linear model predict	apomorphine
most likely therapeutic target for scc db	ECT
most likely therapeutic target for scc db	lithium
critical percentage	hippocampal
critical percentage	Demoralization
critical percentage	stimulation
critical percentage	psychotropics
critical percentage	reported
critical percentage	death
pathophysiology of psychiatric disorder	hippocampal
pathophysiology of psychiatric disorder	stimulation
pathophysiology of psychiatric disorder	reported
pathophysiology of psychiatric disorder	death
likely various methodological factor	health-based
likely various methodological factor	lithium
adult female sprague-dawley rat	lithium
assess	apomorphine
body weight	components
ovariectomised rat	Other
copyright	Other
morbidity of mental disorder among prisoner	hippocampal
morbidity of mental disorder among prisoner	reported
morbidity of mental disorder among prisoner	death
prevalence of mental disorder in taiwanese prisoner	hippocampal
prevalence of mental disorder in taiwanese prisoner	reported
prevalence of mental disorder in taiwanese prisoner	death
patient with major depressive disorder treat with duloxetine for 6 month	hippocampal
patient with major depressive disorder treat with duloxetine for 6 month	design
patient with major depressive disorder treat with duloxetine for 6 month	reported
patient with major depressive disorder treat with duloxetine for 6 month	death
patient with major depressive disorder treat with duloxetine for 6 month	lithium
significant psychosocial	complement
second lead cause of disability worldwide by 2020	first-onset
second lead cause of disability worldwide by 2020	hippocampal
second lead cause of disability worldwide by 2020	EDT
second lead cause of disability worldwide by 2020	psychotropics
second lead cause of disability worldwide by 2020	reported
second lead cause of disability worldwide by 2020	death
second lead cause of disability worldwide by 2020	mood
mood disorder	components
mood disorder	hippocampal
mood disorder	reported
mood disorder	death
mood disorder	mood
erythropoietin	lithium
increase in hippocampal volume	apomorphine
increase in hippocampal volume	hippocampal
have propose include activation of anti-apoptotic signalling pathway	apomorphine
potential importance of glycogen synthase kinase 3-beta	stimulation
potential importance of glycogen synthase kinase 3-beta	death
potential importance of glycogen synthase kinase 3-beta	lithium
publish association between EPO administration	lithium
patient with mood disorder	components
patient with mood disorder	hippocampal
patient with mood disorder	design
patient with mood disorder	reported
patient with mood disorder	death
patient with mood disorder	mood
pharmacogenetic study of epo treatment in patient with mood disorder	electronic
pharmacogenetic study of epo treatment in patient with mood disorder	first-onset
pharmacogenetic study of epo treatment in patient with mood disorder	components
pharmacogenetic study of epo treatment in patient with mood disorder	hippocampal
pharmacogenetic study of epo treatment in patient with mood disorder	design
pharmacogenetic study of epo treatment in patient with mood disorder	stimulation
pharmacogenetic study of epo treatment in patient with mood disorder	psychotropics
pharmacogenetic study of epo treatment in patient with mood disorder	reported
pharmacogenetic study of epo treatment in patient with mood disorder	death
pharmacogenetic study of epo treatment in patient with mood disorder	mood
pharmacogenetic study of epo treatment in patient with mood disorder	lithium
low-income country	Other
human prion disease	framework
human prion disease	lithium
invariably fatal	Other
beta-sheet rich conformer of physiological prp	lithium
inhibitor	Other
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	biomarker
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	addiction
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	electronic
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	complement
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	fear
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	framework
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	hippocampal
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	fasting
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	design
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	stimulation
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	psychotropics
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	reported
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	death
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	mood
first clinical study with pq912 in subject with biomarker-proven alzheimer 's disease	lithium
treatment-related pharmacodynamic effect	first-onset
treatment-related pharmacodynamic effect	hippocampal
treatment-related pharmacodynamic effect	stimulation
treatment-related pharmacodynamic effect	psychotropics
treatment-related pharmacodynamic effect	reported
treatment-related pharmacodynamic effect	death
treatment-related pharmacodynamic effect	mood
tailor to patient population with early ad	electronic
tailor to patient population with early ad	design
tailor to patient population with early ad	lithium
capture by various measure	health-based
main treatment for schizophrenia	first-onset
main treatment for schizophrenia	hippocampal
main treatment for schizophrenia	design
main treatment for schizophrenia	stimulation
main treatment for schizophrenia	psychotropics
main treatment for schizophrenia	ECT
main treatment for schizophrenia	reported
main treatment for schizophrenia	death
main treatment for schizophrenia	mood
schizophrenia treatment	first-onset
schizophrenia treatment	hippocampal
schizophrenia treatment	design
schizophrenia treatment	stimulation
schizophrenia treatment	psychotropics
schizophrenia treatment	ECT
schizophrenia treatment	reported
schizophrenia treatment	death
schizophrenia treatment	mood
mitochondrial outer membrane	Other
severe encephalopathy mental retardation	lithium
neurological disorder of type ii rhm	electronic
neurological disorder of type ii rhm	apomorphine
neurological disorder of type ii rhm	components
neurological disorder of type ii rhm	hippocampal
neurological disorder of type ii rhm	reported
neurological disorder of type ii rhm	death
pleiotropic tissue effect	Other
role in modulation of nitric oxide diffusion	Other
aerobic metabolism	lithium
lipid metabolism disorder	CYB5R3
lipid metabolism disorder	hippocampal
lipid metabolism disorder	reported
lipid metabolism disorder	death
lipid metabolism disorder	lithium
cause by disorder in synapse in disturbance of lipid metabolism	CYB5R3
cause by disorder in synapse in disturbance of lipid metabolism	first-onset
cause by disorder in synapse in disturbance of lipid metabolism	hippocampal
cause by disorder in synapse in disturbance of lipid metabolism	EDT
cause by disorder in synapse in disturbance of lipid metabolism	psychotropics
cause by disorder in synapse in disturbance of lipid metabolism	reported
cause by disorder in synapse in disturbance of lipid metabolism	death
cause by disorder in synapse in disturbance of lipid metabolism	mood
cause by disorder in synapse in disturbance of lipid metabolism	lithium
increase societal issue associate with high rate of substance abuse	biomarker
increase societal issue associate with high rate of substance abuse	first-onset
increase societal issue associate with high rate of substance abuse	hippocampal
increase societal issue associate with high rate of substance abuse	EDT
increase societal issue associate with high rate of substance abuse	stimulation
increase societal issue associate with high rate of substance abuse	psychotropics
increase societal issue associate with high rate of substance abuse	reported
increase societal issue associate with high rate of substance abuse	death
increase societal issue associate with high rate of substance abuse	mood
increase societal issue associate with high rate of substance abuse	lithium
considerable use of psychotropic	first-onset
considerable use of psychotropic	hippocampal
considerable use of psychotropic	EDT
considerable use of psychotropic	psychotropics
considerable use of psychotropic	reported
considerable use of psychotropic	death
considerable use of psychotropic	mood
use of psychotropic among child with asd in Denmark	CYB5R3
use of psychotropic among child with asd in Denmark	first-onset
use of psychotropic among child with asd in Denmark	hippocampal
use of psychotropic among child with asd in Denmark	EDT
use of psychotropic among child with asd in Denmark	psychotropics
use of psychotropic among child with asd in Denmark	reported
use of psychotropic among child with asd in Denmark	death
use of psychotropic among child with asd in Denmark	mood
be change in use of antidepressant	addiction
be change in use of antidepressant	first-onset
be change in use of antidepressant	fear
be change in use of antidepressant	framework
be change in use of antidepressant	hippocampal
be change in use of antidepressant	fasting
be change in use of antidepressant	design
be change in use of antidepressant	EDT
be change in use of antidepressant	psychotropics
be change in use of antidepressant	reported
be change in use of antidepressant	death
be change in use of antidepressant	mood
most often prescribe	Other
two year	Demoralization
psychiatric comorbidity	stimulation
limited use in youngest child	CYB5R3
limited use in youngest child	first-onset
limited use in youngest child	hippocampal
limited use in youngest child	EDT
limited use in youngest child	psychotropics
limited use in youngest child	reported
limited use in youngest child	death
limited use in youngest child	mood
mainly due to increase in use of adhd medication	first-onset
mainly due to increase in use of adhd medication	hippocampal
mainly due to increase in use of adhd medication	EDT
mainly due to increase in use of adhd medication	psychotropics
mainly due to increase in use of adhd medication	ECT
mainly due to increase in use of adhd medication	reported
mainly due to increase in use of adhd medication	death
mainly due to increase in use of adhd medication	mood
previous study	electronic
child with asd	CYB5R3
contribution of past to extent of opioid prescription	CYB5R3
contribution of past to extent of opioid prescription	ECT
have propose as transdiagnostic construct	complement
have propose as transdiagnostic construct	hippocampal
have propose as transdiagnostic construct	Demoralization
have propose as transdiagnostic construct	EDT
have propose as transdiagnostic construct	stimulation
have propose as transdiagnostic construct	reported
have propose as transdiagnostic construct	mood
impact of intervention on death fear	addiction
impact of intervention on death fear	fear
impact of intervention on death fear	framework
impact of intervention on death fear	components
impact of intervention on death fear	health-based
impact of intervention on death fear	fasting
impact of intervention on death fear	design
impact of intervention on death fear	death
significant reduction in death anxiety	complement
significant reduction in death anxiety	components
significant reduction in death anxiety	psychotropics
significant reduction in death anxiety	reported
significant reduction in death anxiety	death
significant reduction in death anxiety	lithium
treatment efficacy	first-onset
treatment efficacy	complement
treatment efficacy	hippocampal
treatment efficacy	stimulation
treatment efficacy	psychotropics
treatment efficacy	reported
treatment efficacy	death
treatment efficacy	mood
give small number of included study need	electronic
give small number of included study need	lithium
use of internet media	first-onset
use of internet media	hippocampal
use of internet media	EDT
use of internet media	psychotropics
use of internet media	reported
use of internet media	death
use of internet media	mood
use of internet media	lithium
site	Other
clinician with complex treatment challenge	first-onset
clinician with complex treatment challenge	hippocampal
clinician with complex treatment challenge	stimulation
clinician with complex treatment challenge	psychotropics
clinician with complex treatment challenge	reported
clinician with complex treatment challenge	death
clinician with complex treatment challenge	mood
pro-ana website use	biomarker
pro-ana website use	first-onset
pro-ana website use	hippocampal
pro-ana website use	EDT
pro-ana website use	psychotropics
pro-ana website use	reported
pro-ana website use	death
pro-ana website use	mood
pervasive generalize negative emotional construct present in psychiatric disorder	complement
pervasive generalize negative emotional construct present in psychiatric disorder	hippocampal
pervasive generalize negative emotional construct present in psychiatric disorder	Demoralization
pervasive generalize negative emotional construct present in psychiatric disorder	stimulation
pervasive generalize negative emotional construct present in psychiatric disorder	psychotropics
pervasive generalize negative emotional construct present in psychiatric disorder	reported
pervasive generalize negative emotional construct present in psychiatric disorder	death
pervasive generalize negative emotional construct present in psychiatric disorder	mood
ubiquitous affective-laden factor	Other
revise NEO Personality Inventory	mood
english-speaking sample of patient	addiction
english-speaking sample of patient	fear
english-speaking sample of patient	framework
english-speaking sample of patient	fasting
english-speaking sample of patient	design
its capacity account for demoralization-related variance in neo pi-r	first-onset
its capacity account for demoralization-related variance in neo pi-r	hippocampal
neo pi-r item pool	Other
hallmark feature of schizophrenia	design
hallmark feature of schizophrenia	ECT
prefrontal cortex function	Other
human	framework
cognition	Other
cognition from that attribute to motor symptom	Other
direct observation of activity of daily living skill	biomarker
direct observation of activity of daily living skill	hippocampal
infiltration of perivascular macrophage into brain with secretion of viral protein	CYB5R3
infiltration of perivascular macrophage into brain with secretion of viral protein	components
infiltration of perivascular macrophage into brain with secretion of viral protein	hippocampal
infiltration of perivascular macrophage into brain with secretion of viral protein	stimulation
infiltration of perivascular macrophage into brain with secretion of viral protein	psychotropics
infiltration of perivascular macrophage into brain with secretion of viral protein	reported
infiltration of perivascular macrophage into brain with secretion of viral protein	death
infiltration of perivascular macrophage into brain with secretion of viral protein	lithium
catb neurotoxicity	Other
oxidative species	Other
macrophage expose to cocaine	hippocampal
macrophage expose to cocaine	stimulation
macrophage expose to cocaine	psychotropics
macrophage expose to cocaine	reported
macrophage expose to cocaine	death
catb secretion from hiv-1 infected macrophage	hippocampal
catb secretion from hiv-1 infected macrophage	stimulation
catb secretion from hiv-1 infected macrophage	psychotropics
catb secretion from hiv-1 infected macrophage	reported
catb secretion from hiv-1 infected macrophage	death
catb secretion from hiv-1 infected macrophage	lithium
mdm	Other
high risk for functional impairment	stimulation
later life	Other
consequence for medical care of elderly group of patient	first-onset
consequence for medical care of elderly group of patient	design
consequence for medical care of elderly group of patient	EDT
consequence for medical care of elderly group of patient	mood
patient with functional movement disorder	hippocampal
patient with functional movement disorder	design
patient with functional movement disorder	reported
patient with functional movement disorder	death
vulnerability factor for mental disorder	hippocampal
vulnerability factor for mental disorder	reported
vulnerability factor for mental disorder	death
cognitive benefit of antithrombotic treatment	biomarker
cognitive benefit of antithrombotic treatment	first-onset
cognitive benefit of antithrombotic treatment	complement
cognitive benefit of antithrombotic treatment	hippocampal
cognitive benefit of antithrombotic treatment	stimulation
cognitive benefit of antithrombotic treatment	psychotropics
cognitive benefit of antithrombotic treatment	ECT
cognitive benefit of antithrombotic treatment	reported
cognitive benefit of antithrombotic treatment	death
cognitive benefit of antithrombotic treatment	mood
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	CYB5R3
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	electronic
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	first-onset
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	complement
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	apomorphine
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	framework
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	components
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	hippocampal
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	Demoralization
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	fasting
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	EDT
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	stimulation
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	psychotropics
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	reported
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	death
clinical effectiveness of long-term psychological treatment for people with type of personality disorder	mood
they availability	Other
low intensity intervention for people with personality disorder	framework
low intensity intervention for people with personality disorder	hippocampal
low intensity intervention for people with personality disorder	fasting
low intensity intervention for people with personality disorder	reported
low intensity intervention for people with personality disorder	death
subthreshold symptom	Other
first episode of psychosis	addiction
first episode of psychosis	fear
first episode of psychosis	framework
first episode of psychosis	fasting
first episode of psychosis	design
as other early characteristic of illness onset	electronic
as other early characteristic of illness onset	psychotropics
as other early characteristic of illness onset	lithium
severe characterize by substantial clinical heterogeneity	complement
severe characterize by substantial clinical heterogeneity	hippocampal
severe characterize by substantial clinical heterogeneity	stimulation
severe characterize by substantial clinical heterogeneity	psychotropics
severe characterize by substantial clinical heterogeneity	reported
severe characterize by substantial clinical heterogeneity	death
severe characterize by substantial clinical heterogeneity	mood
severe characterize by substantial clinical heterogeneity	lithium
such heterogeneity	lithium
antihyperalgesic effect	Other
possible oxidative damage in different region of brain induce by its inflammatory reaction	CYB5R3
possible oxidative damage in different region of brain induce by its inflammatory reaction	components
possible oxidative damage in different region of brain induce by its inflammatory reaction	hippocampal
possible oxidative damage in different region of brain induce by its inflammatory reaction	stimulation
possible oxidative damage in different region of brain induce by its inflammatory reaction	psychotropics
possible oxidative damage in different region of brain induce by its inflammatory reaction	reported
possible oxidative damage in different region of brain induce by its inflammatory reaction	death
possible oxidative damage in different region of brain induce by its inflammatory reaction	mood
behavioral response in swiss mouse	first-onset
behavioral response in swiss mouse	hippocampal
behavioral response in swiss mouse	EDT
behavioral response in swiss mouse	stimulation
behavioral response in swiss mouse	psychotropics
behavioral response in swiss mouse	reported
behavioral response in swiss mouse	death
behavioral response in swiss mouse	mood
extract	Other
augment in colitis-induced animal in relation to disease group	components
augment in colitis-induced animal in relation to disease group	lithium
potential impairment of central nervous system function cause	first-onset
potential impairment of central nervous system function cause	hippocampal
potential impairment of central nervous system function cause	EDT
potential impairment of central nervous system function cause	stimulation
potential impairment of central nervous system function cause	psychotropics
potential impairment of central nervous system function cause	reported
potential impairment of central nervous system function cause	death
potential impairment of central nervous system function cause	mood
treatment-seeking group of native Americans	first-onset
treatment-seeking group of native Americans	hippocampal
treatment-seeking group of native Americans	stimulation
treatment-seeking group of native Americans	psychotropics
treatment-seeking group of native Americans	reported
treatment-seeking group of native Americans	death
treatment-seeking group of native Americans	mood
potential of methylenedioxymethamphetamine	stimulation
potential of methylenedioxymethamphetamine	death
potential of methylenedioxymethamphetamine	lithium
potential problem of neurotoxicity	stimulation
potential problem of neurotoxicity	death
young people	framework
young people	fasting
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	addiction
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	complement
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	fear
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	framework
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	hippocampal
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	health-based
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	fasting
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	design
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	stimulation
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	psychotropics
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	reported
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	death
efficacy of repetitive transcranial magnetic stimulation in sample of young people aged	lithium
severe psychopathological condition	Other
selection of latest international literature include recent study	electronic
selection of latest international literature include recent study	framework
selection of latest international literature include recent study	EDT
selection of latest international literature include recent study	lithium
management of disorder for those	hippocampal
management of disorder for those	EDT
management of disorder for those	stimulation
management of disorder for those	psychotropics
management of disorder for those	reported
management of disorder for those	death
universal prevention for depression in young people	complement
universal prevention for depression in young people	framework
universal prevention for depression in young people	fasting
public health intervention to unique need of population	addiction
public health intervention to unique need of population	fear
public health intervention to unique need of population	framework
public health intervention to unique need of population	health-based
public health intervention to unique need of population	fasting
public health intervention to unique need of population	design
public health intervention to unique need of population	death
public health intervention to unique need of population	mood
public health intervention to unique need of population	lithium
Florida	Other
other risk factor among homeless individual in Tampa	CYB5R3
retrospective chart review on adult homeless patient see at two free clinic site operate by Tampa Bay Street Medicine	CYB5R3
retrospective chart review on adult homeless patient see at two free clinic site operate by Tampa Bay Street Medicine	Demoralization
retrospective chart review on adult homeless patient see at two free clinic site operate by Tampa Bay Street Medicine	design
retrospective chart review on adult homeless patient see at two free clinic site operate by Tampa Bay Street Medicine	lithium
mortality risk	Other
study	electronic
alcohol use	electronic
alcohol use	first-onset
alcohol use	hippocampal
alcohol use	EDT
alcohol use	stimulation
alcohol use	psychotropics
alcohol use	reported
alcohol use	death
alcohol use	mood
age	hippocampal
age	stimulation
age	psychotropics
age	reported
age	death
higher rate of anemia	stimulation
higher rate of anemia	ECT
more prevalent in homeless population than in general population	CYB5R3
more prevalent in homeless population than in general population	lithium
higher morbidity than homeless man	CYB5R3
higher morbidity than homeless man	stimulation
higher morbidity than homeless man	ECT
lower in study population than general population	electronic
lower in study population than general population	health-based
lower in study population than general population	design
lower in study population than general population	lithium
critical need for mental health initiative	Demoralization
critical need for mental health initiative	death
critical need for mental health initiative	mood
critical need for mental health initiative	lithium
onset at youth	lithium
various psychosocial problem with potential impact on psychiatric pharmacotherapy	health-based
various psychosocial problem with potential impact on psychiatric pharmacotherapy	stimulation
various psychosocial problem with potential impact on psychiatric pharmacotherapy	death
dna	Other
gene function	Other
schizophrenia	design
schizophrenia	ECT
course of pharmacotherapeutic intervention	ECT
crossroads between gene	lithium
precision medicine approach epigenetic profile	lithium
steeper slope of decline	Other
schizophrenia	design
schizophrenia	ECT
effect of age on brain measure	CYB5R3
effect of age on brain measure	components
effect of age on brain measure	hippocampal
effect of age on brain measure	stimulation
effect of age on brain measure	psychotropics
effect of age on brain measure	reported
effect of age on brain measure	death
moderator of relationship between age	components
moderator of relationship between age	hippocampal
moderator of relationship between age	stimulation
moderator of relationship between age	psychotropics
moderator of relationship between age	reported
moderator of relationship between age	death
moderator of relationship between age	lithium
age effect on GM indicate	biomarker
age effect on GM indicate	CYB5R3
age effect on GM indicate	hippocampal
age effect on GM indicate	stimulation
age effect on GM indicate	psychotropics
age effect on GM indicate	reported
age effect on GM indicate	death
effect of schizophrenia on GM early in illness	electronic
effect of schizophrenia on GM early in illness	design
effect of schizophrenia on GM early in illness	psychotropics
effect of schizophrenia on GM early in illness	ECT
increase rate of relapse among patient with schizophrenia	design
increase rate of relapse among patient with schizophrenia	ECT
response to medication treatment include therapeutic	first-onset
response to medication treatment include therapeutic	hippocampal
response to medication treatment include therapeutic	stimulation
response to medication treatment include therapeutic	psychotropics
response to medication treatment include therapeutic	ECT
response to medication treatment include therapeutic	reported
response to medication treatment include therapeutic	death
response to medication treatment include therapeutic	mood
prone	Other
return of fear	addiction
return of fear	fear
return of fear	framework
return of fear	health-based
return of fear	fasting
return of fear	design
return of fear	lithium
effect fast on fear acquisition	addiction
effect fast on fear acquisition	fear
effect fast on fear acquisition	framework
effect fast on fear acquisition	health-based
effect fast on fear acquisition	fasting
effect fast on fear acquisition	design
pavlovian fear conditioning paradigm	addiction
pavlovian fear conditioning paradigm	fear
pavlovian fear conditioning paradigm	framework
pavlovian fear conditioning paradigm	health-based
pavlovian fear conditioning paradigm	fasting
pavlovian fear conditioning paradigm	design
enzyme-linked immunosorbent assay	Other
fear extinction retention	addiction
fear extinction retention	fear
fear extinction retention	framework
fear extinction retention	health-based
fear extinction retention	fasting
fear extinction retention	design
fear extinction retention	lithium
remote fear memory	addiction
remote fear memory	electronic
remote fear memory	fear
remote fear memory	framework
remote fear memory	health-based
remote fear memory	fasting
remote fear memory	design
negative relationship with fear response in spontaneous recovery test	addiction
negative relationship with fear response in spontaneous recovery test	fear
negative relationship with fear response in spontaneous recovery test	framework
negative relationship with fear response in spontaneous recovery test	components
negative relationship with fear response in spontaneous recovery test	health-based
negative relationship with fear response in spontaneous recovery test	fasting
negative relationship with fear response in spontaneous recovery test	design
fear memory formation	addiction
fear memory formation	electronic
fear memory formation	fear
fear memory formation	framework
fear memory formation	health-based
fear memory formation	fasting
fear memory formation	design
extinction-based therapy for fear-related disorder	addiction
extinction-based therapy for fear-related disorder	CYB5R3
extinction-based therapy for fear-related disorder	first-onset
extinction-based therapy for fear-related disorder	fear
extinction-based therapy for fear-related disorder	framework
extinction-based therapy for fear-related disorder	hippocampal
extinction-based therapy for fear-related disorder	health-based
extinction-based therapy for fear-related disorder	fasting
extinction-based therapy for fear-related disorder	design
extinction-based therapy for fear-related disorder	reported
extinction-based therapy for fear-related disorder	death
different profile of efficacy in children/adolescents	CYB5R3
different profile of efficacy in children/adolescents	complement
different profile of efficacy in children/adolescents	psychotropics
key priority for future research in each of area of investigation	apomorphine
key priority for future research in each of area of investigation	EDT
have answer	Other
spirit of Open Science	Other
embarrassment	Other
statistical method	lithium
Department of Veterans Affairs hospital	lithium
result in marginalization for sufferer	Other
disability	Other
employment	Other
end-of-life care for individual with schizophrenia	design
end-of-life care for individual with schizophrenia	ECT
end-of-life care for individual with schizophrenia	mood
understanding of hospice for patient with schizophrenia	CYB5R3
understanding of hospice for patient with schizophrenia	Demoralization
understanding of hospice for patient with schizophrenia	design
understanding of hospice for patient with schizophrenia	ECT
consent patient end-of-life care decision	design
consent patient end-of-life care decision	mood
importance of mandatory interdisciplinary training practice	EDT
importance of mandatory interdisciplinary training practice	lithium
provision of quality end-of-life care for individual with schizophrenia	design
provision of quality end-of-life care for individual with schizophrenia	ECT
provision of quality end-of-life care for individual with schizophrenia	death
provision of quality end-of-life care for individual with schizophrenia	mood
difference in characteristic of 104 woman diagnose with compulsive buying behaviour treat at three public hospital unit specialize in addiction from January 2004 to December 2015	addiction
difference in characteristic of 104 woman diagnose with compulsive buying behaviour treat at three public hospital unit specialize in addiction from January 2004 to December 2015	complement
difference in characteristic of 104 woman diagnose with compulsive buying behaviour treat at three public hospital unit specialize in addiction from January 2004 to December 2015	fear
difference in characteristic of 104 woman diagnose with compulsive buying behaviour treat at three public hospital unit specialize in addiction from January 2004 to December 2015	framework
difference in characteristic of 104 woman diagnose with compulsive buying behaviour treat at three public hospital unit specialize in addiction from January 2004 to December 2015	Demoralization
difference in characteristic of 104 woman diagnose with compulsive buying behaviour treat at three public hospital unit specialize in addiction from January 2004 to December 2015	health-based
difference in characteristic of 104 woman diagnose with compulsive buying behaviour treat at three public hospital unit specialize in addiction from January 2004 to December 2015	fasting
difference in characteristic of 104 woman diagnose with compulsive buying behaviour treat at three public hospital unit specialize in addiction from January 2004 to December 2015	design
observe for cohabitation status with percentage	hippocampal
observe for cohabitation status with percentage	stimulation
observe for cohabitation status with percentage	psychotropics
observe for cohabitation status with percentage	reported
observe for cohabitation status with percentage	death
method assess from they own perspective	apomorphine
method assess from they own perspective	lithium
productive development	biomarker
productive development	complement
overview of current state of discipline	fear
overview of current state of discipline	apomorphine
overview of current state of discipline	fasting
overview of current state of discipline	design
live time	design
dialectical modification of proportion of certain domain of life-world of live experience	Other
explore	Other
two contemporary model for clinical practice	CYB5R3
two contemporary model for clinical practice	electronic
two contemporary model for clinical practice	complement
two contemporary model for clinical practice	apomorphine
two contemporary model for clinical practice	hippocampal
two contemporary model for clinical practice	Demoralization
two contemporary model for clinical practice	EDT
two contemporary model for clinical practice	stimulation
two contemporary model for clinical practice	psychotropics
two contemporary model for clinical practice	reported
two contemporary model for clinical practice	death
two contemporary model for clinical practice	mood
they bring to challenge of psychiatric care in twentieth-first century	addiction
they bring to challenge of psychiatric care in twentieth-first century	fear
they bring to challenge of psychiatric care in twentieth-first century	framework
they bring to challenge of psychiatric care in twentieth-first century	fasting
they bring to challenge of psychiatric care in twentieth-first century	design
they bring to challenge of psychiatric care in twentieth-first century	stimulation
they bring to challenge of psychiatric care in twentieth-first century	mood
they bring to challenge of psychiatric care in twentieth-first century	lithium
high comorbidity	stimulation
when they developmental peak	biomarker
when they developmental peak	complement
effect of intervention for cmhp in college student	first-onset
effect of intervention for cmhp in college student	EDT
effect of intervention for cmhp in college student	mood
randomize controlled trial	Other
PRISMA guideline	Other
moderate effect size for depression	complement
highest es for depression among university student	complement
highest es for depression among university student	stimulation
diagnostic scheme for psychogenic nonepileptic seizure	hippocampal
diagnostic scheme for psychogenic nonepileptic seizure	EDT
diagnostic scheme for psychogenic nonepileptic seizure	stimulation
diagnostic scheme for psychogenic nonepileptic seizure	reported
age group	hippocampal
age group	stimulation
age group	psychotropics
age group	reported
age group	death
press human right issue	framework
systematic review of quantitative study publish in past decade on CSA in India	CYB5R3
systematic review of quantitative study publish in past decade on CSA in India	electronic
systematic review of quantitative study publish in past decade on CSA in India	ECT
systematic review of quantitative study publish in past decade on CSA in India	mood
systematic review of quantitative study publish in past decade on CSA in India	lithium
clinical nurse specialist ' view of potential influence of mental health portal on nursing practice	complement
clinical nurse specialist ' view of potential influence of mental health portal on nursing practice	hippocampal
clinical nurse specialist ' view of potential influence of mental health portal on nursing practice	EDT
clinical nurse specialist ' view of potential influence of mental health portal on nursing practice	stimulation
clinical nurse specialist ' view of potential influence of mental health portal on nursing practice	psychotropics
clinical nurse specialist ' view of potential influence of mental health portal on nursing practice	reported
clinical nurse specialist ' view of potential influence of mental health portal on nursing practice	death
clinical nurse specialist ' view of potential influence of mental health portal on nursing practice	mood
clinical nurse specialist ' view of potential influence of mental health portal on nursing practice	lithium
acute care patient	design
acute care patient	mood
nurse usability	Other
people with neurosychiatric disorder	framework
people with neurosychiatric disorder	hippocampal
people with neurosychiatric disorder	fasting
people with neurosychiatric disorder	reported
people with neurosychiatric disorder	death
observational	Other
time of increase risk for intimate partner violence	design
12 hiv-positive pregnant woman recruit from clinical setting in South Africa	complement
12 hiv-positive pregnant woman recruit from clinical setting in South Africa	hippocampal
12 hiv-positive pregnant woman recruit from clinical setting in South Africa	stimulation
12 hiv-positive pregnant woman recruit from clinical setting in South Africa	psychotropics
12 hiv-positive pregnant woman recruit from clinical setting in South Africa	reported
12 hiv-positive pregnant woman recruit from clinical setting in South Africa	death
12 hiv-positive pregnant woman recruit from clinical setting in South Africa	mood
12 hiv-positive pregnant woman recruit from clinical setting in South Africa	lithium
hiv shame	Other
context of abusive relationship	components
complexity of bhc	Other
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	biomarker
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	addiction
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	CYB5R3
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	electronic
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	first-onset
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	fear
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	framework
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	hippocampal
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	Demoralization
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	health-based
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	fasting
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	design
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	EDT
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	stimulation
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	psychotropics
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	reported
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	death
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	mood
evidence on cost-effectiveness of intervention in treatment of chronic condition decade after publication of Roine et al. in 2009	lithium
Alcohol Use disorder	hippocampal
Alcohol Use disorder	reported
Alcohol Use disorder	death
furthermore relatively modest	Other
clinical practice	complement
clinical practice	hippocampal
clinical practice	EDT
clinical practice	stimulation
clinical practice	psychotropics
clinical practice	reported
clinical practice	death
clinical practice	mood
in recent year have conduct	EDT
U.S.	Other
individual 's propensity for compulsive eating	EDT
individual 's propensity for compulsive eating	stimulation
individual 's propensity for compulsive eating	mood
115 non-hispanic caucasian young adult university student	lithium
predict	Other
in addition relate to BMI	Other
indirectly related to food addiction in part through ventral striatum activity	biomarker
indirectly related to food addiction in part through ventral striatum activity	addiction
indirectly related to food addiction in part through ventral striatum activity	first-onset
indirectly related to food addiction in part through ventral striatum activity	complement
indirectly related to food addiction in part through ventral striatum activity	fear
indirectly related to food addiction in part through ventral striatum activity	framework
indirectly related to food addiction in part through ventral striatum activity	hippocampal
indirectly related to food addiction in part through ventral striatum activity	fasting
indirectly related to food addiction in part through ventral striatum activity	design
indirectly related to food addiction in part through ventral striatum activity	stimulation
utility of food addiction in weight gain prevention research	addiction
utility of food addiction in weight gain prevention research	fear
utility of food addiction in weight gain prevention research	framework
utility of food addiction in weight gain prevention research	components
utility of food addiction in weight gain prevention research	fasting
utility of food addiction in weight gain prevention research	design
utility of food addiction in weight gain prevention research	stimulation
outcome	Other
age 14 of lifetime case present by age 24	hippocampal
age 14 of lifetime case present by age 24	Demoralization
age 14 of lifetime case present by age 24	design
age 14 of lifetime case present by age 24	stimulation
age 14 of lifetime case present by age 24	psychotropics
age 14 of lifetime case present by age 24	reported
age 14 of lifetime case present by age 24	death
age 14 of lifetime case present by age 24	lithium
financial burden associate with mental illness	psychotropics
highly effective	hippocampal
highly effective	Demoralization
highly effective	EDT
highly effective	stimulation
highly effective	reported
highly effective	mood
most commonly prescribe atypical antipsychotic olanzapine	CYB5R3
most commonly prescribe atypical antipsychotic olanzapine	complement
drug-naive schizophrenic patient with normal mif expression	CYB5R3
drug-naive schizophrenic patient with normal mif expression	apomorphine
drug-naive schizophrenic patient with normal mif expression	design
activation of appetite-related amp-activated protein kinase	first-onset
activation of appetite-related amp-activated protein kinase	apomorphine
activation of appetite-related amp-activated protein kinase	hippocampal
activation of appetite-related amp-activated protein kinase	lithium
mif expression	Other
associate	Other
role of increase hypothalamic mif expression in metabolic dysfunction	design
role of increase hypothalamic mif expression in metabolic dysfunction	lithium
potential pharmacogenomic value of MIF genotype determination	electronic
potential pharmacogenomic value of MIF genotype determination	first-onset
potential pharmacogenomic value of MIF genotype determination	apomorphine
potential pharmacogenomic value of MIF genotype determination	components
potential pharmacogenomic value of MIF genotype determination	hippocampal
potential pharmacogenomic value of MIF genotype determination	stimulation
potential pharmacogenomic value of MIF genotype determination	psychotropics
potential pharmacogenomic value of MIF genotype determination	reported
potential pharmacogenomic value of MIF genotype determination	death
potential pharmacogenomic value of MIF genotype determination	mood
potential pharmacogenomic value of MIF genotype determination	lithium
innovative tool deal with mental disorder	hippocampal
innovative tool deal with mental disorder	reported
innovative tool deal with mental disorder	death
health care	death
health care	mood
health care	lithium
design for health-based electronic game model	addiction
design for health-based electronic game model	CYB5R3
design for health-based electronic game model	electronic
design for health-based electronic game model	fear
design for health-based electronic game model	apomorphine
design for health-based electronic game model	framework
design for health-based electronic game model	components
design for health-based electronic game model	health-based
design for health-based electronic game model	fasting
design for health-based electronic game model	design
design for health-based electronic game model	death
design for health-based electronic game model	mood
design for health-based electronic game model	lithium
design	components
design	health-based
design	design
model of behavior change	addiction
model of behavior change	CYB5R3
model of behavior change	electronic
model of behavior change	fear
model of behavior change	apomorphine
model of behavior change	framework
model of behavior change	fasting
model of behavior change	design
model of behavior change	stimulation
model of behavior change	mood
present	psychotropics
in second phase develop in field of diabetes	complement
in second phase develop in field of diabetes	lithium
people	framework
people	fasting
highest rating from perspective of subject	stimulation
change behavior	addiction
change behavior	fear
change behavior	framework
change behavior	fasting
change behavior	design
change behavior	stimulation
change behavior	mood
diabetes with educational content	lithium
could apply	Other
child	CYB5R3
general paediatric	Other
common	Other
context of psychologically base therapy	Other
major public health issue	addiction
major public health issue	fear
major public health issue	framework
major public health issue	health-based
major public health issue	fasting
major public health issue	design
major public health issue	death
major public health issue	mood
major public health issue	lithium
antenatal period	Other
common transdiagnostic symptom associate with wide range of developmental health problem	biomarker
common transdiagnostic symptom associate with wide range of developmental health problem	complement
common transdiagnostic symptom associate with wide range of developmental health problem	hippocampal
common transdiagnostic symptom associate with wide range of developmental health problem	EDT
common transdiagnostic symptom associate with wide range of developmental health problem	stimulation
common transdiagnostic symptom associate with wide range of developmental health problem	reported
common transdiagnostic symptom associate with wide range of developmental health problem	death
common transdiagnostic symptom associate with wide range of developmental health problem	mood
common transdiagnostic symptom associate with wide range of developmental health problem	lithium
severity	CYB5R3
adult	lithium
utero exposure to tobacco	Other
reason for aggressive behaviour	complement
reason for aggressive behaviour	Demoralization
underlying developmental health problem	biomarker
underlying developmental health problem	complement
underlying developmental health problem	EDT
underlying developmental health problem	ECT
underlying developmental health problem	death
underlying developmental health problem	mood
underlying developmental health problem	lithium
trial for many neurological disorder	hippocampal
trial for many neurological disorder	reported
trial for many neurological disorder	death
barrier to its use in neurological practice	first-onset
barrier to its use in neurological practice	hippocampal
barrier to its use in neurological practice	EDT
barrier to its use in neurological practice	psychotropics
barrier to its use in neurological practice	reported
barrier to its use in neurological practice	death
barrier to its use in neurological practice	mood
efficacy of action of nac in rodent model of hemorrhagic stroke	CYB5R3
efficacy of action of nac in rodent model of hemorrhagic stroke	electronic
efficacy of action of nac in rodent model of hemorrhagic stroke	complement
efficacy of action of nac in rodent model of hemorrhagic stroke	apomorphine
efficacy of action of nac in rodent model of hemorrhagic stroke	hippocampal
efficacy of action of nac in rodent model of hemorrhagic stroke	death
efficacy of action of nac in rodent model of hemorrhagic stroke	mood
world	Other
depressive disorder	hippocampal
depressive disorder	reported
depressive disorder	death
interface with alter activity within human brain for therapeutic purpose	biomarker
interface with alter activity within human brain for therapeutic purpose	CYB5R3
interface with alter activity within human brain for therapeutic purpose	framework
interface with alter activity within human brain for therapeutic purpose	components
interface with alter activity within human brain for therapeutic purpose	hippocampal
interface with alter activity within human brain for therapeutic purpose	ECT
essential for modern psychiatrist	Other
United States Food	Other
promise	Other
quarter of population	lithium
